Post‐FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy

作者：A. Tefferi, Maymona G. Abdelmagid, Jeanne M Palmer, A. Al-Kali, C. A. Yi, A. Matin, H. Alkhateeb, T. Badar, Yassin Bashir, Kaaren K. Reichard, Rong He, Animesh Pardanani, N. Gangat · 发表于：American journal of hematology/oncology · 年份：2025 · DOI：10.1002/ajh.70203 · 被引用次数：5 · 研究领域：Medicine

Real-world experience using momelotinib as first-line JAK2 inhibitor therapy in myelofibrosis. Anemia response was moderate (23%) while treatment-emergent adverse events included nephropathy (29%) and peripheral neuropathy (20%).